![Christine Cvijic](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Christine Cvijic
Directeur Financier/CFO chez Neurogene, Inc.
Fortune : 2 M $ au 31/05/2024
Postes actifs de Christine Cvijic
Sociétés | Poste | Début | Fin |
---|---|---|---|
Neurogene, Inc.
![]() Neurogene, Inc. BiotechnologyHealth Technology Neurogene, Inc. focuses on developing disease modifying therapeutics for severe neurologic diseases. Its pipeline includes multiple gene therapy products for ultra-rare diseases, as well as a novel technology that has the potential for use in monogenic autism spectrum disorders and indications not well suited for gene therapy. The company was founded by Rachel McMinn in January 2018 and is headquartered in New York, NY. | Directeur Financier/CFO | 24/09/2019 | - |
President | 24/09/2019 | - |
Historique de carrière de Christine Cvijic
Anciens postes connus de Christine Cvijic
Sociétés | Poste | Début | Fin |
---|---|---|---|
ADVANCED ACCELERATOR APPLICATION SA(ADR) | Directeur/Membre du Conseil | 25/05/2017 | 01/03/2018 |
Independent Dir/Board Member | 25/05/2017 | 01/03/2018 | |
SIO GENE THERAPIES INC. | Directeur Administratif | 01/03/2015 | 01/03/2017 |
Conseiller Juridique Général | 01/03/2015 | 01/03/2017 | |
NPS PHARMACEUTICALS, INC. | Conseiller Juridique Général | 01/02/2014 | 01/02/2015 |
Secrétaire Général | 01/02/2014 | 01/02/2015 | |
SAVIENT PHARMACEUTICALS INC | Corporate Officer/Principal | 17/02/2011 | 02/02/2012 |
ImClone LLC
![]() ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Conseiller Juridique Général | 01/02/2011 | 01/02/2011 |
Secrétaire Général | 01/02/2011 | 01/02/2011 | |
Neumentum, Inc.
![]() Neumentum, Inc. Pharmaceuticals: MajorHealth Technology Neumentum, Inc. engages in the provision of pharmaceutical services. It specializes in non-opioid analgesic and neurology specialty where patient with acute and chronic pain. The company was founded by R. Scott Shively and Joseph V. Pergolizzi, Jr. on April 6, 2017 and is headquartered in Palo Alto, CA. | Directeur/Membre du Conseil | 01/03/2017 | - |
Fondateur | 01/03/2017 | - | |
DENDREON CORPORATION | Conseiller Juridique Général | 28/02/2012 | - |
Secrétaire Général | 28/02/2012 | - |
Formation de Christine Cvijic
Fordham University | Graduate Degree |
Rutgers State University of New Jersey | Undergraduate Degree |
Fordham University School of Law | Graduate Degree |
Statistiques
Internationale
Etats-Unis | 11 |
France | 2 |
Opérationnelle
General Counsel | 4 |
Corporate Secretary | 3 |
Graduate Degree | 2 |
Sectorielle
Health Technology | 9 |
Consumer Services | 4 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 8 |
---|---|
Savient Pharmaceuticals, Inc.
![]() Savient Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Savient Pharmaceuticals, Inc. operates as a specialty biopharmaceutical company, which develops, manufactures and markets pharmaceutical products. The company focuses on developing and commercializing KRYSTEXXA for the treatment of chronic gout in adult patients who do not respond to conventional therapy. It also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. The company was founded in 1980 is headquartered in East Brunswick, NJ. | Health Technology |
Dendreon Corp.
![]() Dendreon Corp. Medical SpecialtiesHealth Technology Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Christopher S. Henney, Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA. | Health Technology |
ImClone LLC
![]() ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Health Technology |
Sio Gene Therapies, Inc.
![]() Sio Gene Therapies, Inc. Pharmaceuticals: MajorHealth Technology Sio Gene Therapies, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. The company was founded on October 31, 2014 and is headquartered in New York, NY. | Health Technology |
NPS Pharmaceuticals, Inc.
![]() NPS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NPS Pharmaceuticals, Inc. developed drugs for bone and mineral disorders. It also developed Natpara for the treatment of adult hypoparathyroidism. The company was founded by Hunter Jackson and Thomas N. Parks on October 22, 1986 and is headquartered in Bedminster, NJ. | Health Technology |
Advanced Accelerator Applications SA
![]() Advanced Accelerator Applications SA Medical SpecialtiesHealth Technology Advanced Accelerator Applications SA is a radiopharmaceutical company, which develops, produces and commercializes molecular nuclear medicine products. The firm offers research and development in medicinal and pharmaceutical therapeutic products mainly focusing in cardiology and neurology. It manufactures both diagnostic and therapeutic MNM products for commercialization. The company was founded by Stefano Buono in 2002 and is headquartered in Rueil-Malmaison Cedex, France. | Health Technology |
Neumentum, Inc.
![]() Neumentum, Inc. Pharmaceuticals: MajorHealth Technology Neumentum, Inc. engages in the provision of pharmaceutical services. It specializes in non-opioid analgesic and neurology specialty where patient with acute and chronic pain. The company was founded by R. Scott Shively and Joseph V. Pergolizzi, Jr. on April 6, 2017 and is headquartered in Palo Alto, CA. | Health Technology |
Neurogene, Inc.
![]() Neurogene, Inc. BiotechnologyHealth Technology Neurogene, Inc. focuses on developing disease modifying therapeutics for severe neurologic diseases. Its pipeline includes multiple gene therapy products for ultra-rare diseases, as well as a novel technology that has the potential for use in monogenic autism spectrum disorders and indications not well suited for gene therapy. The company was founded by Rachel McMinn in January 2018 and is headquartered in New York, NY. | Health Technology |
- Bourse
- Insiders
- Christine Cvijic
- Expérience